Hepatitis B e-antigen negative chronic hepatitis B

Journal of Gastroenterology and Hepatology (Australia)

Volumn 17, Issue SUPPL. 3, 2002, Pages

  Sarin, S K ^a   Satapathy, S K ^a   Chauhan, R ^a  

^a G B PANT HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; RIBAVIRIN;

AGE DISTRIBUTION; ANTIGEN ANTIBODY COMPLEX; ANTIGEN EXPRESSION; ANTIGEN STRUCTURE; CELLULAR IMMUNITY; CHRONIC HEPATITIS; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; ENVIRONMENTAL CHANGE; EPIDEMIOLOGICAL DATA; GENE MUTATION; GENETIC PREDISPOSITION; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMORAL IMMUNITY; NOMENCLATURE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEX DIFFERENCE; VIRUS CARRIER; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 0036457050     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.17.s3.20.x     Document Type: Conference Paper

References (80)

1. Hadziyannis SJ. Anti-HBe positive chronic active hepatitis. In: Szmuness W, Alter H, Maynard J, eds. Viral Hepatitis International Symposium. New York: The Franklin Institute Press, 1981; 683.
2. Lok AS, Hadziyannis SJ, Weller IV et al. Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection. Gut 1984; 25: 1283-7.
3. Hadziyannis SJ, Lieberman HM, Karvountzis GG, Shafritz DA. Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg versus anti-HBe positive carriers of hepatitis B virus. Hepatology 1983; 3: 656-62.
4. Bonino F, Rosina F, Rizzetto M et al. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology 1986; 90: 1268-73.
5. Carman WF, Jacyna MR, Hadziyannis S et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588-91.
6. Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 2000; 31: 1037-44.
7. Knoll A, Rohrhofer A, Kochanowski B, Wurm EM, Jilg W. Prevalence of precore mutants in anti-HBe-positive hepatitis B virus carriers in Germany. J. Med. Virol. 1999; 59: 14-18.
8. Chan HL, Leung NW, Hussain M, Wong ML, Lok AS. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000; 31: 763-8.
9. Choudhury A, Santra A, Choudhury S, Ghos A, Banerji P, Mazumdar DN. Prevalence of hepatitis B in the general population: A rural community based study. Trop. Gastro -enterol. 1999; 200: 75-7.
10. Funk ML, Rosenberg DM, Lok AS. Worldwide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J. Viral Hepat. 2002; 9: 52-61.
11. Matsuyama Y, Omata M, Yokosuka O, Imazeki F, Ito Y, Okuda K. Discordance of hepatitis B e antigen/antibody and hepatitis B virus deoxyribonucleic acid in serum. Analysis of 1063 specimens. Gastroenterology 1985; 89: 1104-8.
12. Shindo M, Hamada K, Koya S, Sokawa Y, Okuno T. The clinical significance of core promoter and precore mutations during the natural course and interferon therapy in patients with chronic hepatitis B. Am. J. Gastroenterol. 1999; 94: 2237-45.
13. Okamoto H, Tsuda F, Akahane Y et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J. Virol. 1994; 68: 8102-10.
14. Brunetto MR, Giarin M, Saracco G et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology. 1993; 105: 845-50.
15. Buckwold VE, Xu Z, Chen M, Yen TS, Ou JH. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J. Virol. 1996; 70: 5845-51.
16. Kazim SN, Wakil SM, Khan LA, Hasnain SE, Sarin SK. Vertical transmission of hepatitis B virus despite maternal lamivudine therapy. Lancet 2002; 27: 1488-9.
17. Chang MH, Hsu HY, Ni YH et al. Precore stop codon mutant in chronic hepatitis B virus infection in children: Its relation to hepatitis B e seroconversion and maternal hepatitis B surface antigen. J. Hepatol. 1998; 28: 915-22.
18. Milich DR, Chen MK, Hughes JL, Jones JE. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: A mechanism for persistence. J. Immunol. 1998; 160: 2013-21.
19. Baumeister MA, Medina-Selby A, Coit D et al. Hepatitis B virus e antigen specific epitopes and limitations of commercial anti-HBe immunoassays. J. Med. Virol. 2000; 60: 256-63.
20. Diepolder HM, Ries G, Jung MC et al. Differential antigen-processing pathways of the hepatitis B virus e and core proteins. Gastroenterology 1999; 116: 650.
21. Kuhrober A, Wild J, Puddollck HP, Chisari FU, Remann J. DNA vaccination with plasmids encoding the intracellular (HBeAg) or secreted (HBeAg) form of the core protein of hepatitis B virus provides T-cell responses of two overlapping Kb and Kd restricted epitopes. Int. Immunol. 1997; 9: 1203-12.
22. Chun YK, Kim JY, Woo HJ et al. No significant correlation exists between core promoter mutations, viral replication, and liver damage in chronic hepatitis B infection. Hepatology 2000; 32: 1154-62.
23. Lok AS, Akarca V, Greeve S. Mutations in the precore region of hepatitis B virus serve to enhance the stability of the secondary structure of the pregenomic encapsidation signal. Proc. Natl Acad. Sci. USA 1994; 91: 4077-81.
24. Talbodec N, Loriot MA, Gigou M et al. Hepatitis B virus precore mutations and HBeAg-negative reactivation of chronic hepatitis B after interferon therapy. Liver 1995; 15: 93-8.
25. Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology 1994; 198: 489-503.
26. Stuyver L, De Gendt S, Van Geyt C et al. A new genotype of hepatitis B virus: Complete genome and phylogenetic relatedness. J. General Virol. 2000; 81: 67-74.
27. Thakur V, Guptan RC, Kazim SN, Malhotra V, Sarin SK. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. J. Gastroenterol. Hepatol. 2002; 17: 165-70.
28. Hadziyannis SJ. Interferon alpha therapy in HBeAg-negative chronic hepatitis B. new data in support of long-term efficacy. J. Hepatol. 2002; 36: 280-2.
29. Lindh M, Anderson AS, Gudal A. Genotypes, nt 1858 variants, and geographical origin of hepatitis B virus, large-scale analysis using a new genotyping method. J. Infect. Dis. 1997; 175: 1285-93.
30. Rodriquez-Frias F, Buti M, Jandi R et al. Hepatitis B virus infection: Precore mutants and its relatedness to viral genotypes and core mutation. Hepatology 1995; 22: 1641-2.
31. Chan HL, Tsang SW, Liew CT et al. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am. J. Gastroenterol. 2002; 97: 406-12.
32. Lindh M, Horal P, Dhillon AP, Norkrans G. Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B. J. Viral Hepat. 2000; 7: 258-67.
33. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000. Summary of a workshop. Gastroenterology 2001; 120: 1828-53.
34. Manesis E, Papatheodoridis GV, Sevastinos V, Cholangites E, Papaiounnou C, Hadziyannis SJ. Significance of HBV viremia levels estimated by quantitative PCR assay in the evaluation of HBeAg-negative chronic HBV infection. J. Hepatol. 2001; 17: 115.
35. Sharma J, Ramchandani M, Singh J, Sharma BC, Sarin SK, Thakur V. Natural history of AntiHBe positive, HBeAg-negative chronic hepatitis B patients - A prospective study. Indian J. Gastroenterol. 2001.
36. Hadziyannis SJ. Hepatitis HBeAg-negative chronic hepatitis B from clinical recognition to pathogenesis and treatment. Viral Hepat. Rev. 1995; 1: 7-36.
37. Guptan RC, Thakur V, Sarin SK, Banerjee DK, Khandekar P. Frequency and clinical profile of precore and surface hepatitis B mutants in Asian-Indian patients with chronic liver disease. Am. J. Gastroenterol. 1996; 91: 1312-17.
38. Brunetto MR, Giarin MM, Oliveri F et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc. Natl Acad. Sci. USA. 1991; 88: 4186-90.
39. Chandra R, Kapoor D, Agarwal SR, Malhotra V, Sakhuja P, Sarin SK. Profile of asymptomatic chronic HBV infection in India. Indian J. Med. Res. 2002; in press.
40. Indian Association for Study of the Liver (INASL). Changing terminology of hepatitis B and C carriers: Consensus statement. Indian J. Gastroenterol. 1999; 28 (Suppl. I): S15-20.
41. Core Working Party for Asia Pacific Consensus on Hepatitis B and C. Consensus statements on the prevention and management of hepatitis B and C in the Asia Pacific region. J. Gastroenterol. Hepatol. 2000; 15: 825-41.
42. Sarin SK. Changing terminology of hepatitis B and C carrier. In: Sarin SK, Okuda K, eds.Hepatitis B and C. Carrier to Cancer New Delhi: Harcourt Press, 2001; 41-53.
43. Hamasaki K, Nakata K, Nagayama Y et al. Changes in the prevalence of HBeAg-negative mutant hepatitis B virus during the course of chronic hepatitis B. Hepatology 1994; 20: 8-14.
44. Liaw YF, Tai DI, Chu CM, Pao CC, Chen TJ. Acute exacerbation in chronic type B hepatitis: Comparison between HBeAg and antibody-positive patients. Hepatology 1987; 7: 20-3.
45. Hadziyznnis SJ, Hadziyannis E, Georgious A et al. HBV reactivation in anti Hbe positive HbsAg carriers. Hepatology 1992; 16: 64A.
46. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 1995; 13: 29-60.
47. Lohr HF, Schlaak JF, Gerken G, Fleisher B, Dienes HP, Meyer BK. Phenotypical analysis and cytokine release of liver -infiltrating and peripheral blood T lymphocytes from patients with chronic hepatitis of different etiology. Liver 1994; 14: 161-6.
48. Guidotti IG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825-9.
49. Larus A, Koskinas J, Avgidis K, Hadziyannis SJ. Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in eantigen-negative patients. J. Viral Hepat. 1998; 5: 241-8.
50. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34: 617-24.
51. Williams SJ, Craig PI, Cooksley WG et al. Randomized controlled trial of recombinant human interferon-alpha A for chronic active hepatitis B. Aust. NZ J. Med. 1990; 20: 9-19.
52. Brook MG, Chan G, Yap I et al. Randomised controlled trial of lymphoblastoid interferon alfa in European men with chronic hepatitis B virus infection. BMJ 1989; 299: 652-6.
53. Brunetto MR, Oliveri F, Rocca G et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 1989; 10: 198-202.
54. Hadziyannis SJ, Bramou T, Makris A, Moussoulis G, Zignengo I, Papaonnoue C. Interferon α-2b treatment of HBeAg-negative serum HBV-DNA positive chronic active hepatitis. Brit. J. Hepatol. 1990; 11 (Suppl.): S133-6.
55. Fattovich G, Farci P, Dugge M et al. A randomized trial of lymphoblastoid interferon in patients with chronic hepatitis B lacking HBeAgepatology. 1992; 15:584-9.
56. Pastore G, Santantonio T, Millela M et al. Anti HBeAg-positive chronic hepatitis B with HBV-DNA in the serum: Response to a 6 month course of lymphoblastoid interferon. J. Hepatol. 1992; 14: 221-5.
57. Brunetto MR, Oliveri F, Colombatto P, Capalbo M, Barbera C, Bonino F. Treatment of chronic anti-HBe-positive hepatitis B with interferon-alpha. J. Hepatol. 1995; 22 (Suppl.): 42-4.
58. Lampertico P, Del Ninno E, Manzin A et al. A randomized, controlled trial of a 24-month course of interferon alfa-2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997; 26: 1621-5.
59. Kako M, Kanai K, Aikawa T et al. Response to interferon α-2a in patients with e antigen negative chronic hepatitis B. J. Clin. Gastroenterol. 1998; 27: 367-8.
60. Guptan RC, Thakur V, Malhotra V, Sarin SK. Low dose recombinant interferon therapy in anti-HBe positive chronic hepatitis B in Asian Indians. J. Gastroenterol. Hepatol. 1988; 1397): 675-9.
61. Alberti A, Fattovich G, Pontisso P, Brollo L, Belussi F, Ruol A. Interferon treatment of anti-HBe positive and HBV-DNA positive chronic hepatitis B. Chemioterapia 1988; 7 (Suppl.): 15-19.
62. Lin CC, Wu JC, Chang TT et al. Long-term evaluation of recombinant interferon alpha 2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in Taiwan. J. Viral Hepat. 2001; 8: 438-46.
63. Brunetto MR, Oliveri F, Coco B et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: A long term cohort study. J. Hepatol. 2002; 36: 263-70.
64. Oliveri F, Santantonio T, Bellati G et al. Long-term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. Am. J. Gastroenterol. 1999; 94: 1366-72.
65. Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121: 101-9.
66. Koreman J, Baker B, Waggoner J et al. Long-term remission of chronic hepatitis B after alpha interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971-5.
67. Papatheodoridis GV, Hadziyannis SJ. Diagnosis and management of precore mutant chronic hepatitis B. J. Viral Hepat. 2001; 8: 311-21.
68. Papatheodoridis GV, Manesis EK, Hadziyannis SJ. Long-term Outcome of Interferon α in Treated and Untreated Patients with HBeAg-negative Chronic Hepatitis B. 2001; 39: 306-13.
69. Papatheodoridis GV, Manesis EK, Hadziyannis SJ. Long-term follow up after initial response to interferon therapy in patients with HBeAg-negative chronic hepatitis B. Hepatology 2000; 32 (Suppl.): 378A.
70. Tassopoulos NC, Volpes R, Pastore G et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29: 889-96.
71. Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV-DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J. Hepatol. 2000; 32: 300-6.
72. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 847-51.
73. Lok ASF, Hussain H, Carsano C et al. Evolution of hepatitis B virus polymerase gene mutation in hepatitis B e antigen negative patients receiving lamivudine therapy. Hepatology 2000; 32: 1145-53.
74. Kazim SN, Guptan RC, Wakil SM, Sudheer K, Sarin SK. Higher efficacy of 'sequential' therapy of lamivudine and interferon compared to lamivudine monotherapy in HBeAg-positive, chronic hepatitis B patients. J. Gastroen-terol. 2002; 17: Abstract.
75. Papatheodoridis GV, Dimon E, Rapti I et al. HBV reactivation and biochemical breakthroughs after initially effective lamivudine therapy in patients with precore mutant HBV related liver disease. Hepatology 2000; 32: 847-51.
76. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32: 635-9.
77. Tatulli I, Francavilla R, Rizzo GL et al. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. J. Hepatol. 2001; 35: 805-10.
78. Hadziyannis S, Alexopoulou A, Papakonstantinou A, Petraki K, Manesis E. Interferon treatment with or without oral ganciclovir in HBeAg-negative chronic hepatitis B: A randomized study. J. Viral Hepat. 2000; 7: 235-40.
79. Cotonat T, Quiroga JA, Lopez-Alcorocho JM et al. Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients. Hepatology 2000; 31: 502-6.
80. Guptan RC, Thakur V, Kazim SN, Sarin SK. Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in HBV-related chronic liver disease patients. J. Gastroenterol. Hepatol. 2002; 17: 765-71.